New hope for frail AML patients: stronger chemo regimens tested
NCT ID NCT04195945
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tests whether giving full-strength chemotherapy (either CPX-351 or a combination called CLAG-M) can help medically less-fit adults with acute myeloid leukemia live longer and achieve remission. About 60 participants will receive one of the two treatments. The goal is to see if these stronger doses, usually given to healthier patients, are safe and effective for frailer individuals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a targeted drug plus donor immune cells fight back against relapsed leukemia?
- Can a Two-Drug combo outsmart a deadly leukemia?
- Can a new pill take on Hard-to-Treat leukemia?
- Leukemia drug cocktail aims to boost remission in High-Risk patients
- Could bone marrow from deceased donors cure blood cancers?